Skip to content
10-Q

Quarterly Report

Quoin Pharmaceuticals, Ltd. QNRX

0001104659-26-056941

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.87M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.59M
Short Term Investments Q1 2026 · Mar 31, 2026 $10.92M
Short Term Investments Q1 2026 · Dec 31, 2025 $14.93M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.12M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.82M
Stockholders Equity Q1 2026 · Mar 31, 2026 $8.77M
Stockholders Equity Q1 2026 · Dec 31, 2025 $13.12M
Stockholders Equity Q1 2026 · Mar 31, 2025 $5.93M
Stockholders Equity Q1 2026 · Dec 31, 2024 $9.2M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.35M
Current Liabilities Q1 2026 · Dec 31, 2025 $5.55M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.27M
Current Assets Q1 2026 · Mar 31, 2026 $15.33M
Current Assets Q1 2026 · Dec 31, 2025 $20.01M
Total Assets Q1 2026 · Mar 31, 2026 $15.69M
Total Assets Q1 2026 · Dec 31, 2025 $20.39M
Sga Expense Q1 2026 · Mar 31, 2026 $1.7M
Sga Expense Q1 2026 · Mar 31, 2025 $1.58M
Rd Expense Q1 2026 · Mar 31, 2026 $3.43M
Rd Expense Q1 2026 · Mar 31, 2025 $2.37M
Net Income Q1 2026 · Mar 31, 2026 −$5M
Net Income Q1 2026 · Mar 31, 2025 −$3.81M